ProShare Advisors LLC increased its position in shares of Alkermes plc (NASDAQ:ALKS – Get Rating) by 2.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,408 shares of the company's stock after buying an additional 684 shares during the period. ProShare Advisors LLC's holdings in Alkermes were worth $768,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in shares of Alkermes by 14.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 186,287 shares of the company's stock worth $4,158,000 after buying an additional 23,151 shares during the period. Duality Advisers LP bought a new stake in shares of Alkermes during the 3rd quarter worth $1,783,000. Teacher Retirement System of Texas boosted its holdings in shares of Alkermes by 3.5% during the 3rd quarter. Teacher Retirement System of Texas now owns 813,538 shares of the company's stock worth $18,166,000 after buying an additional 27,797 shares during the period. Barclays PLC boosted its holdings in shares of Alkermes by 483.7% during the 3rd quarter. Barclays PLC now owns 285,652 shares of the company's stock worth $6,378,000 after buying an additional 236,711 shares during the period. Finally, Hardman Johnston Global Advisors LLC boosted its holdings in shares of Alkermes by 7.0% during the 3rd quarter. Hardman Johnston Global Advisors LLC now owns 5,734,259 shares of the company's stock worth $128,046,000 after buying an additional 376,543 shares during the period. 96.15% of the stock is owned by institutional investors.
Get
Alkermes alerts:
Analysts Set New Price Targets
Several research firms recently issued reports on ALKS. Mizuho upped their price objective on shares of Alkermes from $34.00 to $36.00 and gave the stock a "buy" rating in a report on Tuesday, November 22nd. Bank of America upped their target price on shares of Alkermes from $27.00 to $28.00 in a research note on Sunday, January 8th. StockNews.com cut shares of Alkermes from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 2nd. JPMorgan Chase & Co. cut their target price on shares of Alkermes from $33.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, December 6th. Finally, Piper Sandler upgraded shares of Alkermes from a "neutral" rating to an "overweight" rating and upped their target price for the company from $26.00 to $30.00 in a research note on Thursday, November 3rd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Alkermes currently has an average rating of "Moderate Buy" and an average price target of $29.89.
Alkermes Trading Down 1.0 %
Shares of ALKS stock opened at $27.35 on Friday. Alkermes plc has a 52-week low of $21.75 and a 52-week high of $32.79. The stock has a market cap of $4.49 billion, a price-to-earnings ratio of -35.06 and a beta of 0.59. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.89 and a current ratio of 2.24. The firm has a fifty day moving average of $26.33 and a 200-day moving average of $24.97.
Alkermes (NASDAQ:ALKS – Get Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). The business had revenue of $252.36 million during the quarter, compared to analyst estimates of $271.45 million. Alkermes had a negative net margin of 11.41% and a negative return on equity of 1.10%. The company's quarterly revenue was down 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.02) EPS. On average, equities research analysts forecast that Alkermes plc will post -0.29 earnings per share for the current fiscal year.
Alkermes Profile
(Get Rating)
Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
Read More
- Get a free copy of the StockNews.com research report on Alkermes (ALKS)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Get Rating).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
